People · Operator
Named in public records as an officer, director or promoter · active 2020–2023 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| TearClear Corp. | — | Pharmaceuticals | Series B | $52.4M | $122.5M | 2020 |
| AsclepiX Therapeutics, Inc. | — | Biotechnology | Series A | $28.0M | $83.4M | 2023 |
Robert Dempsey at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Robert Dempsey on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William Link | 1 | 11 |
| Chris Garabedian | 1 | 8 |
| Tyler Stowater | 1 | 7 |
| Richard Harrison | 1 | 6 |
| Steven Altschuler | 1 | 5 |
| Robert Bailey | 1 | 4 |
| Sapna Srivastava | 1 | 3 |
| Ben Askew | 1 | 3 |
| Amir Shojaei | 1 | 3 |
| Richard Heinick | 1 | 3 |
| Jordan Green | 1 | 2 |
| Steve Pazol | 1 | 2 |
| Stuart Raetzman | 1 | 2 |
| Joshua Barer | 1 | 2 |
| Jordan J. Green | 1 | 2 |
| Kevin Hershfield | 1 | 1 |
| Josh Barer | 1 | 1 |
| Aleksander Popel | 1 | 1 |
| Niranjan Pandey | 1 | 1 |
| Jill Tierney | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.